raisavydyexuwowi.blogspot.com
Hematide is in a Phase III trial. Rentohn led Onyx for nearly 15 years, steppinyg down in February 2008as president, CEO, chairmanb and a member of Onyx’s board. At the he helped negotiate a research, developmentr and commercialization partnership with that resulted inthe anti-cancer drug Nexavar. Nexavaf tablets, which cost about $5,000 a montyh in the United States and areapproachiny $1 billion in annual sales, are approved in more than 80 countrie s to treat kidney cancer and 70-pluws countries for liver cancer. Prior to joining Renton was president and COOof Chiron, whichb acquired Cetus in 1991.
Renton had been president of Cetusxsince 1990, COO since 1987 and CFO from 1983 to 1987. Rento n also serves on the boardsof , Cepheid and the Specia l Olympics of Northern California.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment